Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-19-000056
Filing Date
2019-11-06
Accepted
2019-11-06 16:36:27
Documents
62
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20190930.htm   iXBRL 10-Q 2250014
2 EX-31.1 exhibit311q32019.htm EX-31.1 11758
3 EX-31.2 exhibit312q32019.htm EX-31.2 11798
4 EX-32.1 exhibit321q32019.htm EX-32.1 6995
5 EX-32.2 exhibit322q32019.htm EX-32.2 7133
  Complete submission text file 0001714899-19-000056.txt   8378671

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20190930.xsd EX-101.SCH 48476
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20190930_cal.xml EX-101.CAL 70157
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20190930_def.xml EX-101.DEF 270446
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20190930_lab.xml EX-101.LAB 613220
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20190930_pre.xml EX-101.PRE 392580
23 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20190930_htm.xml XML 1568441
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 191196849
SIC: 2836 Biological Products, (No Diagnostic Substances)